Company research
HUTCHMED (China) Ltd
CIK 1648257Updated Nov 6, 2026
SecuritiesHMDCF · OTC · equityHCM · NASDAQ · adr
Historical securities (1)
HNCMF · OTC · equity · closed Jun 10, 2021Name history
Hutchison China MediTech Ltd · through Apr 29, 2021
HMDCF price & chart
Loading TradingView…
OTC:HMDCF on TradingView ↗About the company
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2019 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 454,092,000Source | 1,775,940,000Source | 1,260,868,000Source | 1,297,497,000Source | 1,194,333,000Source | 1,272,889,000Source | 525,562,000Source | 495,214,000Source | 1,753,097,000Source | 1,274,196,000Source | 1,279,773,000Source | 1,029,445,000Source |
| Property, Plant and Equipment, NetUSD | 18,528,000Source | 94,573,000Source | 94,815,000Source | 96,829,000Source | 44,059,000Source | 29,168,000Source | 20,841,000Source | 17,669,000Source | 94,623,000Source | 92,498,000Source | 99,727,000Source | 75,947,000Source |
| GoodwillUSD | 3,088,000Source | 3,064,000Source | 3,015,000Source | 3,064,000Source | 3,259,000Source | 3,332,000Source | 3,088,000Source | 3,186,000Source | 3,112,000Source | 2,990,000Source | 3,064,000Source | 3,137,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 288,000Source | 9,647,000Source | — | 52,000Source | 122,000Source | 194,000Source | 241,000Source | 315,000Source | 8,941,000Source | — | 21,000Source | 85,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 97,082,000Source | 110,719,000Source | 203,953,000Source | 222,996,000Source | 467,502,000Source | 587,441,000Source | 49,940,000Source | 83,360,000Source | 71,330,000Source | 153,958,000Source | 283,589,000Source | 313,278,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 40,332,000Source | 146,967,000Source | 156,916,000Source | 129,203,000Source | 77,078,000Source | 57,953,000Source | 44,623,000Source | 42,758,000Source | 126,750,000Source | 155,537,000Source | 116,894,000Source | 97,988,000Source |
| Inventory, NetUSD | 15,653,000Source | 48,454,000Source | 46,441,000Source | 53,875,000Source | 45,925,000Source | 25,505,000Source | 15,262,000Source | 14,223,000Source | 41,129,000Source | 50,400,000Source | 50,258,000Source | 56,690,000Source |
| Assets, CurrentUSD | 277,081,000Source | 1,592,327,000Source | 1,048,260,000Source | 1,090,485,000Source | 1,022,237,000Source | 1,091,174,000Source | 374,727,000Source | 309,496,000Source | 1,567,342,000Source | 1,066,555,000Source | 1,096,839,000Source | 839,888,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,566,000Source | 3,879,000Source | 6,392,000Source | 9,192,000Source | 9,463,000Source | 9,523,000Source | 5,283,000Source | 6,792,000Source | 3,027,000Source | 4,497,000Source | 4,665,000Source | 8,722,000Source |
| Other Assets, NoncurrentUSD | 6,580,000Source | 40,620,000Source | 37,274,000Source | 39,547,000Source | 45,038,000Source | 24,708,000Source | 6,637,000Source | 6,774,000Source | 20,092,000Source | 15,433,000Source | 14,675,000Source | 15,745,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 116,305,000Source | 534,017,000Source | 508,850,000Source | 497,480,000Source | 342,484,000Source | 259,194,000Source | 158,514,000Source | 122,177,000Source | 501,835,000Source | 502,343,000Source | 536,386,000Source | 392,575,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 66,679,000Source | 87,211,000Source | 87,136,000Source | 86,616,000Source | 86,457,000Source | 84,851,000Source | 69,057,000Source | 66,658,000Source | 87,233,000Source | 87,160,000Source | 87,126,000Source | 86,478,000Source |
| Retained Earnings (Accumulated Deficit)USD | -260,172,000Source | -380,319,000Source | -845,068,000Source | -803,057,000Source | -773,189,000Source | -517,996,000Source | -339,528,000Source | -229,067,000Source | -378,643,000Source | -833,172,000Source | -870,869,000Source | -971,481,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,575,000Source | -5,490,000Source | -9,534,000Source | -7,800,000Source | 1,882,000Source | 5,333,000Source | -5,534,000Source | -400,000Source | -4,532,000Source | -11,585,000Source | -8,163,000Source | -1,903,000Source |
| Stockholders' Equity Attributable to ParentUSD | 313,517,000Source | 1,229,064,000Source | 740,084,000Source | 782,039,000Source | 799,728,000Source | 984,795,000Source | 342,120,000Source | 347,890,000Source | 1,237,926,000Source | 759,929,000Source | 730,541,000Source | 610,367,000Source |
| Additional Paid in Capital, Common StockUSD | 512,585,000Source | 1,527,662,000Source | 1,507,550,000Source | 1,506,280,000Source | 1,484,578,000Source | 1,412,607,000Source | 618,125,000Source | 510,699,000Source | 1,533,868,000Source | 1,517,526,000Source | 1,522,447,000Source | 1,497,273,000Source |
| Liabilities and EquityUSD | 454,092,000Source | 1,775,940,000Source | 1,260,868,000Source | 1,297,497,000Source | 1,194,333,000Source | 1,272,889,000Source | 525,562,000Source | 495,214,000Source | 1,753,097,000Source | 1,274,196,000Source | 1,279,773,000Source | 1,029,445,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 105,345,000Source | 342,349,000Source | 373,288,000Source | 340,863,000Source | 321,856,000Source | 247,715,000Source | 119,387,000Source | 110,605,000Source | 315,775,000Source | 376,562,000Source | 403,027,000Source | 353,903,000Source |
| Operating Lease, Liability, CurrentUSD | 3,497,000Source | — | — | — | — | 3,852,000Source | 2,594,000Source | 3,529,000Source | 2,881,000Source | 2,925,000Source | 3,927,000Source | 3,708,000Source |
| Accounts Payable, CurrentUSD | 23,029,000Source | 43,725,000Source | 43,398,000Source | 54,575,000Source | 51,005,000Source | 28,513,000Source | 25,871,000Source | 26,145,000Source | 45,533,000Source | 42,521,000Source | 36,327,000Source | 71,115,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,500,000Source | 3,109,000Source | — | — | — | 5,957,000Source | 3,278,000Source | 3,714,000Source | 1,852,000Source | 4,089,000Source | 2,860,000Source | 5,196,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 255,000Source | 2,990,000Source | 1,484,000Source | 2,710,000Source |
| Other Liabilities, NoncurrentUSD | 7,460,000Source | 93,042,000Source | 19,305,000Source | 19,294,000Source | 20,210,000Source | 5,522,000Source | 9,010,000Source | 7,858,000Source | — | 10,836,000Source | 11,346,000Source | 12,662,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 24,270,000Source | 12,859,000Source | 11,934,000Source | 17,978,000Source | 52,121,000Source | 28,900,000Source | 24,928,000Source | 25,147,000Source | 13,336,000Source | 11,924,000Source | 12,846,000Source | 26,503,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 1,364,520,000Source | 802,453,000Source | 856,168,000Source | 826,200,000Source | — | — | — | 1,367,275,000Source | 836,110,000Source | 886,336,000Source | 630,996,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 60,625,000Source | — | — | — | — | — | — | 48,432,000Source | 69,480,000Source | — |
| Long-term Debt, Current MaturitiesUSD | — | 25,603,000Source | 26,468,000Source | — | — | 26,883,000Source | — | — | 24,971,000Source | 23,372,000Source | 31,155,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 67,841,000Source | 55,632,000Source | 40,147,000Source | 418,000Source | — | 26,839,000Source | — | 68,189,000Source | 59,434,000Source | 48,189,000Source | 18,104,000Source |
| Short-term InvestmentsUSD | 104,493,000Source | 1,253,801,000Source | 598,500,000Source | 633,172,000Source | 358,698,000Source | 363,007,000Source | 231,074,000Source | 153,928,000Source | 1,295,945,000Source | 682,152,000Source | 602,747,000Source | 317,718,000Source |
cash flow · annual statements
| Line item | Q4 2019 | Q3 2019 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 457,732,000Source | 38,170,000Source | 101,094,000Source | -360,386,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 13,308,000Source | 12,341,000Source | 8,207,000Source | 8,664,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -28,862,000Source | 38,545,000Source | 21,336,000Source | 14,451,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | -9,542,000Source | 772,000Source | -4,135,000Source | 21,213,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | 3,012,000Source | 6,194,000Source | -32,542,000Source | 29,938,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -118,000Source | 5,308,000Source | 2,226,000Source | -3,563,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | — | -64,657,000Source | 497,000Source | 219,258,000Source | -268,599,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -29,410,000Source | -96,060,000Source | -291,136,000Source | 296,588,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 14,148,000Source | 17,933,000Source | 32,612,000Source | 36,664,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 36,064,000Source | 9,071,000Source | 48,084,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 7,836,000Source | -30,667,000Source | 48,660,000Source | -82,763,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | -82,628,000Source | -129,631,000Source | -29,689,000Source | -64,264,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 97,082,000Source | 110,719,000Source | 203,953,000Source | 222,996,000Source | 467,502,000Source | 587,441,000Source | 49,940,000Source | 71,330,000Source | 153,958,000Source | 283,589,000Source | 313,278,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 2,518,000Source | 2,509,000Source | 421,000Source | 150,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 62,411,000Source | 3,587,000Source | 3,728,000Source | 18,891,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 18,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,364,520,000Source | 802,453,000Source | 856,168,000Source | 826,200,000Source | — | — | 1,367,275,000Source | 836,110,000Source | 886,336,000Source | 630,996,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 11,998,000Source | 12,070,000Source | 7,888,000Source | 8,327,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | — | 130,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | 476,896,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 21,000Source | -10,000Source | -86,000Source | -111,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 66,722,000Source | 64,296,000Source | 79,784,000Source | 92,173,000Source |
| GoodwillUSD | — | 3,088,000Source | 3,064,000Source | 3,015,000Source | 3,064,000Source | 3,259,000Source | 3,332,000Source | 3,088,000Source | 3,112,000Source | 2,990,000Source | 3,064,000Source | 3,137,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | 22,651,000Source | 46,469,000Source | 47,295,000Source | 49,753,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 63,610,000Source | 7,192,000Source | 4,509,000Source | -283,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | 2,865,000Source | 2,872,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 49,877,000Source | 40,080,000Source | 36,145,000Source | 9,599,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | — | — | — | 456,909,000Source | 37,729,000Source | 100,780,000Source | -360,835,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 823,000Source | 441,000Source | 314,000Source | 449,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 60,955,000Source | 42,598,000Source | 39,933,000Source | -2,729,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 5,372,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 1,889,000Source | 2,088,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 1,578,000Source | 790,000Source | 5,094,000Source | 174,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | 2,513,000Source | 3,069,000Source | 6,184,000Source | 6,736,000Source |
income statement · annual statements
| Line item | Q4 2019 | Q3 2019 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 548,512,000Source | 630,201,000Source | 837,999,000Source | 426,409,000Source |
| Cost of RevenueUSD | — | — | 336,349,000Source | 348,884,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -39,160,000Source | -43,705,000Source | 18,375,000Source | -407,693,000Source |
| Income Tax Expense (Benefit)USD | — | — | 63,610,000Source | 7,192,000Source | 4,509,000Source | -283,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 823,000Source | 441,000Source | 314,000Source | 449,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 456,909,000Source | 37,729,000Source | 100,780,000Source | -360,835,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.53Source | 0.04Source | 0.12Source | -0.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.52Source | 0.04Source | 0.12Source | -0.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 858,276,608Source | 855,351,683Source | 849,654,296Source | 847,143,540Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 872,891,120Source | 872,829,129Source | 869,196,348Source | 847,143,540Source |
| Interest Expense (non-operating)USD | — | — | 2,865,000Source | 2,872,000Source | — | — |
| Additional Financial Items | ||||||
| Costs and ExpensesUSD | — | — | 587,672,000Source | 673,906,000Source | 819,624,000Source | 834,102,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | 63,728,000Source | 1,884,000Source | 2,283,000Source | 3,280,000Source |
| General and Administrative ExpenseUSD | — | — | 66,722,000Source | 64,296,000Source | 79,784,000Source | 92,173,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 22,651,000Source | 46,469,000Source | 47,295,000Source | 49,753,000Source |
| Interest ExpenseUSD | — | — | — | — | 759,000Source | 652,000Source |
| Investment Income, InterestUSD | — | — | 49,877,000Source | 40,080,000Source | 36,145,000Source | 9,599,000Source |
| Labor and Related ExpenseUSD | — | — | 58,317,000Source | 69,079,000Source | 93,030,000Source | 119,306,000Source |
| Nonoperating Income (Expense)USD | — | — | 60,955,000Source | 42,598,000Source | 39,933,000Source | -2,729,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | 5,372,000Source |
| Research and Development ExpenseUSD | — | — | 148,295,000Source | 212,109,000Source | 302,001,000Source | 386,893,000Source |
| Selling ExpenseUSD | — | — | 36,306,000Source | 48,617,000Source | 53,392,000Source | 43,933,000Source |
Filing attachments
hcm-ex99d1.htm · 6-K · 2026-11-05
Exhibit 99.1 Press Release HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia - Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval - - Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP - Hong Kong, Shanghai & Florham Park, NJ - Thursday, November 5, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today a…
Read attachment ↗hcm-ex99d1.htm · 6-K · 2026-11-02
Exhibit 99.1 Press Release HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan - Follows US FDA new drug application submission in September 2026, marking important global regulatory progress - Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements - - Data selected for ESMO 2026 Presidential Symposium an…
Read attachment ↗hcm-ex99d1.htm · 6-K · 2026-10-29
Exhibit 99.1 Press Release HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia - Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia - - Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition - - Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval - Hong Kong, Shang…
Read attachment ↗hcm-ex99d1.htm · 6-K · 2026-10-27
Exhibit 99.1 Press Release Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 27, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell l…
Read attachment ↗hcm-ex99d1.htm · 6-K · 2026-10-26
Exhibit 99.1 Press Release HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine - ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® - - ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months - - SAFFRON is the first global Phase III trial to show significant p…
Read attachment ↗hcm-ex99d2.htm · 6-K · 2026-10-26
Exhibit 99.2 Press Release HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 - ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting - - Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population - - Offers …
Read attachment ↗